Esther Peters
Esther Peters
Unknown affiliation
Verified email at radboudumc.nl
Title
Cited by
Cited by
Year
Adenosine and selective A2A receptor agonists reduce ischemia/reperfusion injury of rat liver mainly by inhibiting leukocyte activation
N Harada, K Okajima, K Murakami, S Usune, C Sato, K Ohshima, ...
Journal of Pharmacology and Experimental Therapeutics 294 (3), 1034-1042, 2000
164*2000
Acute kidney injury in the ICU: from injury to recovery: reports from the 5th Paris International Conference
R Bellomo, C Ronco, RL Mehta, P Asfar, J Boisramé-Helms, M Darmon, ...
Annals of intensive care 7 (1), 49, 2017
832017
Alkaline phosphatase: a possible treatment for sepsis-associated acute kidney injury in critically ill patients
E Peters, S Heemskerk, R Masereeuw, P Pickkers
American journal of kidney diseases 63 (6), 1038-1048, 2014
712014
α7 nicotinic acetylcholine receptor agonist GTS-21 attenuates ventilator-induced tumour necrosis factor-α production and lung injury
M Kox, JC Pompe, E Peters, M Vaneker, JW Van Der Laak, ...
British journal of anaesthesia 107 (4), 559-566, 2011
572011
A worldwide multicentre evaluation of the influence of deterioration or improvement of acute kidney injury on clinical outcome in critically ill patients with and without …
E Peters, M Antonelli, X Wittebole, R Nanchal, B François, Y Sakr, ...
Critical Care 22 (1), 188, 2018
522018
Alkaline phosphatase protects against renal inflammation through dephosphorylation of lipopolysaccharide and adenosine triphosphate
E Peters, S Geraci, S Heemskerk, MJ Wilmer, A Bilos, B Kraenzlin, ...
British journal of pharmacology 172 (20), 4932-4945, 2015
472015
Alkaline phosphatase as a treatment of sepsis-associated acute kidney injury
E Peters, A van Elsas, S Heemskerk, L Jonk, J van der Hoeven, J Arend, ...
Journal of pharmacology and experimental therapeutics 344 (1), 2-7, 2013
422013
Study protocol for a multicentre randomised controlled trial: Safety, Tolerability, efficacy and quality of life Of a human recombinant alkaline Phosphatase in patients with …
E Peters, RL Mehta, PT Murray, J Hummel, M Joannidis, JA Kellum, ...
BMJ open 6 (9), e012371, 2016
282016
The potential of alkaline phosphatase as a treatment for sepsis-associated acute kidney injury
E Peters, R Masereeuw, P Pickkers
Nephron Clinical Practice 127 (1-4), 144-148, 2014
272014
The involvement of danger-associated molecular patterns in the development of immunoparalysis in cardiac arrest patients
K Timmermans, M Kox, J Gerretsen, E Peters, GJ Scheffer, ...
Critical care medicine 43 (11), 2332-2338, 2015
242015
Short-term hypoxia dampens inflammation in vivo via enhanced adenosine release and adenosine 2B receptor stimulation
D Kiers, B Wielockx, E Peters, LT van Eijk, J Gerretsen, A John, E Janssen, ...
EBioMedicine 33, 144-156, 2018
232018
Effects of a human recombinant alkaline phosphatase on renal hemodynamics, oxygenation and inflammation in two models of acute kidney injury
E Peters, B Ergin, A Kandil, E Gurel-Gurevin, A van Elsas, R Masereeuw, ...
Toxicology and applied pharmacology 313, 88-96, 2016
232016
Effects of the humanized anti-adrenomedullin antibody adrecizumab (HAM8101) on vascular barrier function and survival in rodent models of systemic inflammation and sepsis
C Geven, E Peters, M Schroedter, J Struck, A Bergmann, O McCook, ...
Shock 50 (6), 648-654, 2018
192018
Pharmacokinetic modeling and dose selection in a randomized, double-blind, placebo-controlled trial of a human recombinant alkaline phosphatase in healthy volunteers
E Peters, JAAC Heuberger, R Tiessen, A van Elsas, R Masereeuw, ...
Clinical pharmacokinetics 55 (10), 1227-1237, 2016
142016
Tubular injury biomarkers to detect gentamicin-induced acute kidney injury in the neonatal intensive care unit
D Jansen, E Peters, S Heemskerk, L Koster-Kamphuis, MP Bouw, ...
American journal of perinatology 33 (02), 180-187, 2016
132016
Biodistribution and translational pharmacokinetic modeling of a human recombinant alkaline phosphatase
E Peters, J Stevens, J Arend, Z Guan, W Raaben, P Laverman, ...
International journal of pharmaceutics 495 (1), 122-131, 2015
122015
Effects of a human recombinant alkaline phosphatase during impaired mitochondrial function in human renal proximal tubule epithelial cells
E Peters, T Schirris, AH van Asbeck, J Gerretsen, J Eymael, A Ashikov, ...
European journal of pharmacology 796, 149-157, 2017
92017
36th International Symposium on Intensive Care and Emergency Medicine
RM Bateman, MD Sharpe, JE Jagger, CG Ellis, J Solé-Violán, ...
Critical Care 20 (2), 13-182, 2016
82016
Human recombinant alkaline phosphatase inhibits ex vivo platelet activation in humans
RN Tunjungputri, E Peters, A van der Ven, PG de Groot, Q de Mast, ...
Thrombosis and haemostasis 116 (12), 1111-1121, 2016
42016
Pharmacokinetics, safety and tolerability of human recombinant alkaline phosphatase in healthy volunteers
E Peters, J Arend, R Tiessen, A Van Elsas, R Masereeuw, P Pickkers
Critical Care 19 (1), 1-201, 2015
22015
The system can't perform the operation now. Try again later.
Articles 1–20